91 related articles for article (PubMed ID: 31537377)
1. Gp130 degradation induced by epirubicin contributes to chemotherapy efficacy.
Liu F; Jin H; Shen J; Wu D; Tian Y; Huang C
Biochem Biophys Res Commun; 2019 Nov; 519(3):572-578. PubMed ID: 31537377
[TBL] [Abstract][Full Text] [Related]
2. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
4. Discovery of bazedoxifene analogues targeting glycoprotein 130.
Song D; Yu W; Ren Y; Zhu J; Wan C; Cai G; Guo J; Zhang W; Kong L
Eur J Med Chem; 2020 Aug; 199():112375. PubMed ID: 32388278
[TBL] [Abstract][Full Text] [Related]
5. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
6. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.
Shi Y; Zhou W; Cheng L; Chen C; Huang Z; Fang X; Wu Q; He Z; Xu S; Lathia JD; Ping Y; Rich JN; Bian XW; Bao S
Cell Death Differ; 2017 Jan; 24(1):167-180. PubMed ID: 27740621
[TBL] [Abstract][Full Text] [Related]
7. Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells.
Wu X; Xiao H; Wang R; Liu L; Li C; Lin J
Curr Cancer Drug Targets; 2016; 16(7):631-8. PubMed ID: 26373715
[TBL] [Abstract][Full Text] [Related]
8. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
9. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
[TBL] [Abstract][Full Text] [Related]
10. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro.
Lo YL; Wang W
Chem Biol Interact; 2013 Oct; 205(3):188-97. PubMed ID: 23867903
[TBL] [Abstract][Full Text] [Related]
11. Ulinastatin reduces the resistance of liver cancer cells to epirubicin by inhibiting autophagy.
Song B; Bian Q; Shao CH; Li G; Liu AA; Jing W; Liu R; Zhang YJ; Zhou YQ; Hu XG; Jin G
PLoS One; 2015; 10(3):e0120694. PubMed ID: 25815885
[TBL] [Abstract][Full Text] [Related]
12. TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy.
Xie JM; Li B; Yu HP; Gao QG; Li W; Wu HR; Qin ZH
Cancer Res; 2014 Sep; 74(18):5127-38. PubMed ID: 25085248
[TBL] [Abstract][Full Text] [Related]
13. Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration.
Arulanandam R; Geletu M; Feracci H; Raptis L
Exp Cell Res; 2010 Mar; 316(5):875-86. PubMed ID: 19852956
[TBL] [Abstract][Full Text] [Related]
14. Progesterone augments epirubicin-induced apoptosis in HA22T/VGH cells by increasing oxidative stress and upregulating Fas/FasL.
Chang WT; Hsieh BS; Cheng HL; Lee KT; Chang KL
J Surg Res; 2014 May; 188(2):432-41. PubMed ID: 24594218
[TBL] [Abstract][Full Text] [Related]
15. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
[TBL] [Abstract][Full Text] [Related]
16. Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A.
Izgi K; Iskender B; Sakalar C; Arslanhan A; Yuksek EH; Hizar E; Canatan H
Anticancer Agents Med Chem; 2017; 17(3):404-414. PubMed ID: 27039926
[TBL] [Abstract][Full Text] [Related]
17. Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation.
Radtke S; Wüller S; Yang XP; Lippok BE; Mütze B; Mais C; de Leur HS; Bode JG; Gaestel M; Heinrich PC; Behrmann I; Schaper F; Hermanns HM
J Cell Sci; 2010 Mar; 123(Pt 6):947-59. PubMed ID: 20200229
[TBL] [Abstract][Full Text] [Related]
18. Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity.
Wu J; Guo W; Lin SZ; Wang ZJ; Kan JT; Chen SY; Zhu YZ
Cell Death Dis; 2016 Aug; 7(8):e2339. PubMed ID: 27537522
[TBL] [Abstract][Full Text] [Related]
19. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.
Siegsmund MJ; Stendler A; Kreukler C; Köhrmann KU; Alken P
Eur Urol; 1997; 31(3):365-70. PubMed ID: 9129933
[TBL] [Abstract][Full Text] [Related]
20. [A comparative study on in vitro chemosensitivity of urotherial cancers to three anthracyclines].
Yamada S; Deguchi T; Nezasa S; Kawamoto S; Ehara H; Takahashi Y; Okano M; Fujimoto Y; Isogai K; Kawada Y
Gan To Kagaku Ryoho; 1996 Sep; 23(10):1339-41. PubMed ID: 8831750
[No Abstract] [Full Text] [Related]
[Next] [New Search]
